Jiangsu Xinrui Pharmaceutical Co., Ltd., established in March 2012, is a major investment project in Nantong City, Jiangsu Province. In 2016, it has been included in“Major Project Bank”of supply-side reform of China National Development and Reform Commission. Located in Rugao Port Chemical New Materials Industrial Park in Rugao City, Jiangsu Province, the company is specialized in manufacturing APIs, intermediates, and advanced intermediates for pharmaceutical use, with main products for anti-hypertension, anti-hyperlipidemia and anti-hyperglycemia. Thanks to our commitment to independent research and development, and cooperation and innovation, we hold a number of independent intellectual property rights and a Class 1 new drug clinical approval.
With registered capital of RMB 153.6956 million, Our factory covers an area of 88,342.8 square meters, with construction area for production more than 50,000 square meters, Class I and II warehouse area 3,000 square meters, and Class III workshop and warehouse 14,000 square meters.
Waste treatment facilities cover more than 10,000 square meters. With more than 20 million RMB invested for environmental protection, our capacity forsewage treatment reaches 1,000 cubic meters per day, which meets the needs for both our current operation and future development.
We have designed and built our site according to US FDA requirements, including GMP workshops, state-of-artanalytical laboratories and R & D laboratories, and a comprehensive quality assurance system. Seventeen invention patents have been authorised by China competent authorities. Currently we have an automation production line for valsartan with annual production capacity of 550 tons, and several production lines for Resuvastatin calcium with annual capacity 100 tons, 4-fluoro-3phenoxybenzaldehyde with capacity of 500 tons ,and 3,3-dimethylbutyryl chloride with capacity 500 tons. 40% of our products are exported to Europe and the United States, with a strong professional image and brand.